Scrip    Clinica    RAJ    Scrip Clinical Research    AnimalPharm   
Email ID
Password
Forgotten your password?
Sign me in automatically next time
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Product Approvals
|
Clinical Trials
|
Product Filings
|
Product Safety
|
Preclinical
|
Product Delays
|
Research & Development - Clinical Trials
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK Promote your vacancy here
Deal with Ono the first for Concordia's novel Ras inhibitor
02 September 2010
Ono Pharmaceutical has acquired exclusive development and commercialisation rights in Japan to Concordia Pharmaceuticals' direct Ras inhibitor salirasib, which it will develop initially for pancreatic cancer. The Japanese firm will pay undisclosed ...
Otonomy raises $38.5 million to advance Meniere's disease treatment
31 August 2010
Otonomy, a private US biopharmaceutical company focused on disorders of the inner and middle ear, has raised $38.5 million in a series B round. The company said the funds would be used to support its two lead programmes, OTO-104 and OTO-203, through ...
Hope high for "personalised medicine" in melanoma
26 August 2010
Hopes are high that inhibition of the mutated BRAF oncogene, present in about 40-60% of melanomas, will become a strategy for "personalised medicine" in the difficult-to-treat disease, based on the promising results of an early clinical trial of a ...
Voclosporin licensed in China for transplantation
26 August 2010
Isotechnika Pharma saw its share price jump up by 30% earlier this week following news that it had signed a development and commercialisation deal with China's 3SBio for voclosporin, an investigational next generation calcineurin inhibitor for the ...
Pipeline progress at Oxford BioMedica as H1 losses reach £2.9 million
25 August 2010
Widening losses at Oxford BioMedica in the first half of 2010 were tempered by positive news on a number of the company's product development programmes. These included possibilities for accelerating clinical trials with ProSavin, the gene-based ...
 
2010 Scrip 100 - Mixed fortunes on the R&D front
23 August 2010
Continued problems with anti-obesity drugs, more measures designed to improve R&D efficiency, and the approval of first-in-class therapeutics such as Amgen's Prolia and Dendreon's Provenge: the first ...
Liver cancer becomes more preventable and treatable
12 August 2010
New drugs to treat viral hepatitis infection, coupled with renewed interest from companies in developing therapies to treat liver cancer following Nexavar's approval, have improved prospects for both ...
Scrip Asia 100 - CROs find a Seoul mate in South Korea
29 June 2010
As a location for clinical research, South Korea resembles many countries in more traditional geographies, with its modern infrastructure and well educated English-speaking staff. Small wonder its ...
 
GW high on pipeline of cannabis extracts
23 August 2010
GW Pharma has enjoyed recent success with its cannabinoid extract product Sativex (nabiximols), which is now approved in the UK and Spain as an add-on therapy for spasticity in multiple sclerosis, ...
Anti-obesity drugs: an inventor's perspective
20 November 2009
After years of anti-obesity disappointments, Orexigen's Contrave, Vivus's Qnexa and Arena's lorcaserin stand on the verge of being filed with the US FDA. Professor Michael Cowley, inventor of ...
Face-to-face: Evotec CEO tells of turnaround
02 October 2009
Since becoming CEO of Evotec Dr Werner Lanthaler has overseen a string of deals as well as upheavals at the company. He spoke to Scrip's Simon Varcoe about how the German firm has been transformed ...
 
GSK's malaria vaccine sails towards uncharted territory
05 November 2009
GlaxoSmithKline will enter unknown regulatory waters when it eventually comes to seek approval of its paediatric malaria vaccine, RTS,S, the most advanced in development for this disease. The ...
Private investment round-up: June 2009
22 July 2009
The total investments secured by private companies slumped once more in June, disappointing onlookers hoping that May's healthy performance was a sign of recovery in the market, a Scrip analysis has ...
Cancer drugs: getting more for your money – by Karol Sikora
11 May 2009
Cancer treatment is undergoing a revolution, driven by ageing populations, advanced technologies and an increasingly informed society. Health economics considerations and top-up payments are gaining ...
 
Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict
01 December 2008
For the last half-century, despite its many limitations warfarin has been the mainstay of treatment for patients with venous and arterial thromboembolic disease. During the past decade, a number of ...
Deforolimus (AP23573) a novel mTOR inhibitor in clinical development
01 December 2008
mTOR was determined to be a promising anticancer target and several drug inhibitors of mTOR are currently in clinical development. Rapamycin (RAP) was the first mTOR inhibitor discovered. However, ...
Emerging oral drugs for multiple sclerosis
01 September 2008
Background: Therapy for multiple sclerosis (MS) has changed dramatically over the past decade, yielding significant progress in the treatment of relapsing/remitting and secondary progressive MS. ...
 
COMPANY/ORGANISATION
CONDITION
GEOGRAPHY
DRUG
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
RAJ
Scrip Clinical Research
Animal Pharm